Dima Shulkin: Comparing HALP and PIV for Mortality Prediction in ACS
Dima Shulkin, Co-Founder and CTO at RobotDreams GmbH, shared a post on LinkedIn about a recent article by Azmi Eyiol, published in Journal of Clinical Medicine, adding:
“A new multicenter study in acute coronary syndrome puts two simple blood-based scores under the microscope: PIV, a combined immune-inflammation value, and HALP, a score built from hemoglobin, albumin, lymphocytes and platelets.
In 1.134 hospitalized patients, HALP predicted mortality better than PIV, with an AUROC of 0.722 versus 0.619, meaning it separated higher-risk from lower-risk patients more reliably.
The striking part is that this signal came from routine admission labs, not from a complex new test.”
Title: Pan-Immune-Inflammatory Value (PIV) and HALP Score as Independent Prognostic Indicators in Acute Coronary Syndrome Patients
Authors: Azmi Eyiol, Hatice Eyiol, Ahmet Yilmaz, Hasan Sari
Stay updated with Hemostasis Today.
-
Jun 15, 2026, 17:20Megan Adediran: Small Act, Massive Impact – Celebrating Blood Donor Day
-
Jun 15, 2026, 16:52Alejandro González Veliz: A Modern Approach to Anticoagulant Management
-
Jun 15, 2026, 16:20New Therapeutic Strategies Targeting Iron Metabolism
-
Jun 15, 2026, 15:43Antonio Paul: Donor Safety Is More Than a Sterile Needle
-
Jun 15, 2026, 15:36Alejandro González Veliz: A Coronary Calcium Score of Zero Doesn’t Always Mean Zero Risk
-
Jun 15, 2026, 15:35Tareq Abadl: Your Blood Tells Your Story – Even in the Shape of Its Cells
-
Jun 15, 2026, 15:34Three Days of Learning, Collaboration, and Community at EHC 2026
-
Jun 15, 2026, 15:31Abdul Mannan: What if Our First Move in Acquired Haemophilia A is Costing Frail Patients Time?
-
Jun 15, 2026, 14:11Alba Maiques Diaz: Completion of My Tenure in the YoungEHA Committee at the EHA